C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
The molecular basis of breast cancer pathological phenotypes
Yujing J. Heng,Susan C. Lester,Gary M. Tse,Rachel E. Factor,Kimberly H. Allison,Laura C. Collins,Yunn-Yi Chen,Kristin C. Jensen,Kristin C. Jensen,Nicole B. Johnson,Jong Cheol Jeong,Rahi Punjabi,Sandra J. Shin,Kamaljeet Singh,Gregor Krings,David A. Eberhard,Puay Hoon Tan,Konstanty Korski,Frederic M. Waldman,David A. Gutman,Melinda E. Sanders,Jorge S. Reis-Filho,Sydney R Flanagan,Deena Ma Gendoo,Deena Ma Gendoo,Gregory M. Chen,Benjamin Haibe-Kains,Benjamin Haibe-Kains,Giovanni Ciriello,Katherine A. Hoadley,Charles M. Perou,Andrew H. Beck +31 more
TL;DR: The integration of morphological with molecular data has the potential to refine breast cancer classification, predict response to therapy, enhance the understanding of breast cancer biology, and improve clinical management.
Journal ArticleDOI
PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).
Minetta C. Liu,Brandelyn N. Pitcher,Elaine R. Mardis,Sherri R. Davies,Paula N Friedman,Jacqueline E. Snider,Tammi L. Vickery,Jerry P. Reed,Katherine DeSchryver,Baljit Singh,William J. Gradishar,Edith A. Perez,Silvana Martino,Marc L. Citron,Larry Norton,Eric P. Winer,Clifford A. Hudis,Lisa A. Carey,Philip S. Bernard,Torsten O. Nielsen,Charles M. Perou,Matthew J. Ellis,William T. Barry +22 more
TL;DR: PAM50 intrinsic breast cancer subtypes are prognostic independent of standard clinicopathologic factors and PAM50 gene signatures were highly prognostic but did not predict for improved outcomes with DD anthracycline- and taxane-based therapy.
Journal ArticleDOI
Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.
Charles J. Bowerman,James D. Byrne,Kevin S. Chu,Allison N. Schorzman,Amanda W. Keeler,Candice A. Sherwood,Jillian L. Perry,James C. Luft,David B. Darr,Allison M. Deal,Mary E. Napier,William C. Zamboni,Norman E. Sharpless,Charles M. Perou,Joseph M. DeSimone +14 more
TL;DR: The potential of nanotechnology to improve the therapeutic index of chemotherapies and rescue therapeutic efficacy to treat nonresponsive cancers is demonstrated.
Journal ArticleDOI
Integrated RNA and DNA sequencing improves mutation detection in low purity tumors.
Matthew D. Wilkerson,Christopher R. Cabanski,Christopher R. Cabanski,Wei Sun,Katherine A. Hoadley,Vonn Walter,Lisle E. Mose,Melissa A. Troester,Peter S. Hammerman,Peter S. Hammerman,Joel S. Parker,Charles M. Perou,D. Neil Hayes +12 more
TL;DR: In this article, the authors developed a method, called UNCeqR, that detects somatic mutations by integrating patient-matched RNA-seq and DNA-WES, and demonstrated that the integrated DNA and RNA model outperformed the DNA- WES only model.
Journal ArticleDOI
Cell-State Transitions Regulated by SLUG Are Critical for Tissue Regeneration and Tumor Initiation
Sarah Phillips,Sarah Phillips,Aleix Prat,Maja Sedic,Maja Sedic,Theresa A. Proia,Ania Wronski,Ania Wronski,Sohini Mazumdar,Adam Skibinski,Adam Skibinski,Stephanie H. Shirley,Charles M. Perou,Grace Gill,Piyush Gupta,Charlotte Kuperwasser,Charlotte Kuperwasser +16 more
TL;DR: It is shown that in the absence of SLUG, mammary stem cell activity necessary for tissue regeneration and cancer initiation is lost and that SLUG plays a dual role in repressing luminal epithelial differentiation while unlocking stem cell transitions necessary for tumorigenesis.